摘要
目的:探讨甲状腺乳头状癌钠碘转运体(sodium/iodide symporter,NIS)蛋白表达对131I疗效的预测及与BRAF基因突变的关系。方法:收集甲状腺乳头状癌根治术后行131I治疗的患者60例,临床随访131I疗效分为完全缓解和不完全缓解,不完全缓解组再分为摄碘和不摄碘。免疫组化法对患者肿瘤原发灶NIS蛋白表达进行分析,根据表达强弱分为0,1,2,3分。应用Pyrosequencing焦磷酸测序技术对肿瘤原发灶BRAF基因突变进行分析。对131I疗效各组和BRAF突变两组的NIS蛋白表达水平进行统计分析。结果:甲状腺乳头状癌NIS蛋白染色阳性颗粒主要定位于细胞浆,阳性评分为1.45±0.77。131I治疗完全缓解患者29例,其NIS蛋白水平(1.62±0.86)与不完全缓解组(1.29±0.64)无统计学差异(P=0.100)。但对不完全缓解组进一步研究发现,不摄碘组NIS蛋白水平(1.00±0.60)显著低于摄碘组(1.47±0.61),P=0.043。伴BRAF基因突变患者检出47例(78.3%),其NIS蛋白评分(1.34±0.73)与携带野生型基因患者(1.85±0.80)比较差异有统计学意义,P=0.035。结论:131I疗效与肿瘤原发灶NIS蛋白表达水平没有明显关系,但不摄碘的持续不缓解患者常伴有肿瘤NIS蛋白表达降低和缺失;伴BRAF基因突变患者其NIS蛋白表达降低,分化程度更差。
Objective:To explore the correlation between expression of NIS and BRAF mutation, clinicpathological parameters and results of 1311 treatment in papillary thyroid cancer. Methods: All 60 papillary thyroid cancer patients undergoing surgery and 131^I treatment were reviewed and divided into complete remission group and incomplete remission group. Immunohistochemical analysis of NIS was performed, scored 0, 1, 2, 3 by intensity. And BRAF mutation was analyzed. Results: Staining of NIS was mostly at cytoplasm in papillary thyroid cancer, and scored 1.45 ± 0.77 on average. 48.3% (29/60)were observed as complete remission, and no differences were found between the two groups (P =0. 100). However if the incomplete remission group was subdivided into radioiodine uptake and no uptake, the latter group was with lower NIS protein than the former group ( P = 0. 043 ). BRAF mutation was confirmed in 78.3% (47/60) patients, and lower NIS protein level was found with BRAF mutation group, compared with wild type BRAF gene (P = 0. 035 ). Conclusion:NIS protein level was not correlated the result of 131^I treatment in papillary thyroid cancer patients, but incurred patients with no 131^ I uptake always got a lower NIS protein level. Patients with BRAF mutation may have obviously lower NIS protein level.
出处
《现代肿瘤医学》
CAS
2013年第4期746-748,共3页
Journal of Modern Oncology
基金
教育部科学技术研究重点项目(编号:210269)
湖北省教育厅科研项目(编号:B20101206)
宜昌市科技计划项目(编号:A01301-08)